{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:56:39Z","timestamp":1781625399002,"version":"3.54.5"},"reference-count":120,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Advanced therapies (biologic agents and small molecules) for inflammatory bowel diseases (IBD) have radically changed the management of these diseases during the last decade. Data about these drugs in patients with hepatic disorders derive mainly from real-life studies, as these conditions often represent an exclusion criterion from pivotal drug developmental trials. However, IBD patients sometimes have concomitant liver diseases. Nonalcoholic fatty liver disease is the most prevalent hepatic comorbidity, whereas viral hepatitis, primary sclerosing cholangitis, primary biliary cholangitis, autoimmune hepatitis, and hepatic vascular disorders are less frequent. This review aimed at describing the real-life data about the use of advanced therapies for IBD in patients with concomitant hepatobiliary disorders. Hepatitis B virus and hepatitis C virus infections do not represent an absolute contraindication for novel IBD therapeutic agents. Data from the literature suggest a safe hepatobiliary profile of biologic agents and small molecules in the case of nonalcoholic fatty liver disease, autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis, and portal vein thrombosis. Consequently, although the liver disease does not affect a different therapeutic approach in patients with concomitant IBD and liver disease, a close risk\/benefit analysis for each drug should be performed in these patients, especially in cirrhotic patients and in the postliver transplant setting.<\/jats:p>","DOI":"10.1093\/ibd\/izac189","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T14:29:03Z","timestamp":1661869743000},"page":"1477-1487","source":"Crossref","is-referenced-by-count":4,"title":["Use of IBD Drugs in Patients With Hepatobiliary Comorbidities: Tips and Tricks"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-8192","authenticated-orcid":false,"given":"Sara","family":"Massironi","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Center for Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo Hospital , Monza , Italy"},{"name":"Department of Medicine and Surgery, University of Milano-Bicocca , Monza , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Pirola","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Center for Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo Hospital , Monza , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Mulinacci","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Center for Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo Hospital , Monza , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ciaccio","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Center for Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo Hospital , Monza , Italy"},{"name":"Department of Medicine and Surgery, University of Milano-Bicocca , Monza , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Vigan\u00f2","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Center for Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo Hospital , Monza , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Palermo","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Center for Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo Hospital , Monza , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Zilli","sequence":"additional","affiliation":[{"name":"Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele , Milan , Italy"},{"name":"Vita-Salute San Raffaele University , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Invernizzi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Center for Autoimmune Liver Diseases, European Reference Network on Hepatological Diseases (ERN RARE-LIVER), San Gerardo Hospital , Monza , Italy"},{"name":"Department of Medicine and Surgery, University of Milano-Bicocca , Monza , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele , Milan , Italy"},{"name":"Vita-Salute San Raffaele University , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"issue":"46","key":"2023090111593252300_CIT0001","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.3748\/wjg.v11.i46.7227","article-title":"Extraintestinal manifestations in inflammatory bowel disease","volume":"11","author":"Danese","year":"2005","journal-title":"World J Gastroenterol."},{"issue":"7","key":"2023090111593252300_CIT0002","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/ibd\/izy051","article-title":"Nonalcoholic fatty liver disease in inflammatory bowel disease: prevalence and risk factors","volume":"24","author":"Principi","year":"2018","journal-title":"Inflamm Bowel Dis."},{"issue":"7","key":"2023090111593252300_CIT0003","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology."},{"issue":"6","key":"2023090111593252300_CIT0004","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/ibd\/izaa189","article-title":"Prevalence of nonalcoholic fatty liver disease in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"27","author":"Lin","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"2023090111593252300_CIT0005","doi-asserted-by":"crossref","first-page":"e0170034","DOI":"10.1371\/journal.pone.0170034","article-title":"Intestinal bacteria composition and translocation of bacteria in inflammatory bowel disease","volume":"12","author":"Vrakas","year":"2017","journal-title":"PLoS One."},{"issue":"1","key":"2023090111593252300_CIT0006","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/ajg.2008.4","article-title":"Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study","volume":"104","author":"Loras","year":"2009","journal-title":"Am J Gastroenterol."},{"issue":"6","key":"2023090111593252300_CIT0007","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J. Crohns Colitis."},{"issue":"13","key":"2023090111593252300_CIT0008","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.3748\/wjg.v20.i13.3516","article-title":"Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease","volume":"20","author":"Sansone","year":"2014","journal-title":"World J Gastroenterol."},{"issue":"1","key":"2023090111593252300_CIT0009","first-page":"118","article-title":"Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy","volume":"31","author":"Lee","year":"2013","journal-title":"Clin Exp Rheumatol."},{"issue":"5","key":"2023090111593252300_CIT0010","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/1756-185X.12154","article-title":"Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs","volume":"16","author":"Lee","year":"2013","journal-title":"Int. J. Rheum. Dis."},{"issue":"4","key":"2023090111593252300_CIT0011","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatol. Baltim. Md."},{"issue":"6","key":"2023090111593252300_CIT0012","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease","volume":"15","author":"Kucharzik","year":"2021","journal-title":"J. Crohns Colitis."},{"issue":"10","key":"2023090111593252300_CIT0013","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1136\/gutjnl-2020-322362","article-title":"Recent advances in clinical practice: epidemiology of autoimmune liver diseases","volume":"70","author":"Trivedi","year":"2021","journal-title":"Gut."},{"issue":"1","key":"2023090111593252300_CIT0014","first-page":"17","article-title":"Prevalence of inflammatory bowel disease among patients with primary sclerosing cholangitis in Iran","volume":"17","author":"Hadizadeh","year":"2016","journal-title":"Arab J. Gastroenterol. Off. Publ. Pan-Arab Assoc. Gastroenterol."},{"issue":"6","key":"2023090111593252300_CIT0015","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1053\/j.gastro.2021.08.032","article-title":"Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"161","author":"Barberio","year":"2021","journal-title":"Gastroenterology"},{"issue":"4","key":"2023090111593252300_CIT0016","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1053\/jhep.2001.23316","article-title":"Autoimmune overlap syndromes","volume":"33","author":"Woodward","year":"2001","journal-title":"Hepatol. Baltim. Md"},{"issue":"5","key":"2023090111593252300_CIT0017","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.clinre.2011.10.007","article-title":"PSC, AIH and overlap syndrome in inflammatory bowel disease","volume":"36","author":"Trivedi","year":"2012","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"4","key":"2023090111593252300_CIT0018","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3748\/wjg.v9.i4.878","article-title":"-L. Primary biliary cirrhosis and ulcerative colitis: a case report and review of literature","volume":"9","author":"Xiao","year":"2003","journal-title":"World J Gastroenterol."},{"issue":"3","key":"2023090111593252300_CIT0019","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1053\/j.gastro.2010.05.026","article-title":"Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism","volume":"139","author":"Novacek","year":"2010","journal-title":"Gastroenterology."},{"issue":"11","key":"2023090111593252300_CIT0020","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.4254\/wjh.v13.i11.1534","article-title":"Liver involvement in inflammatory bowel disease: What should the clinician know","volume":"13","author":"Losurdo","year":"2021","journal-title":"World J. Hepatol."},{"issue":"5","key":"2023090111593252300_CIT0021","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/art.41580","article-title":"Venous thromboembolism risk with JAK inhibitors: a meta-analysis","volume":"73","author":"Yates","year":"2021","journal-title":"Arthritis Rheumatol. Hoboken NJ."},{"issue":"3","key":"2023090111593252300_CIT0022","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.crohns.2011.10.003","article-title":"Portal vein thrombosis in inflammatory bowel diseases: a single-center case series","volume":"6","author":"Maconi","year":"2012","journal-title":"J. Crohns Colitis."},{"key":"2023090111593252300_CIT0023","doi-asserted-by":"crossref","first-page":"744505","DOI":"10.3389\/fmed.2021.744505","article-title":"Epidemiology and risk factors of portal venous system thrombosis in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"8","author":"Lin","year":"2021","journal-title":"Front. Med."},{"issue":"2","key":"2023090111593252300_CIT0024","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/ibd\/izaa053","article-title":"The natural history, treatments, and outcomes of portal vein thrombosis in patients with inflammatory bowel disease","volume":"27","author":"Naymagon","year":"2021","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2023090111593252300_CIT0025","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/MEG.0b013e32830263cb","article-title":"Late onset ulcerative colitis complicating a patient with Budd-Chiari syndrome: a case report and review of the literature","volume":"21","author":"Vassiliadis","year":"2009","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"10159","key":"2023090111593252300_CIT0026","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"James","year":"2018","journal-title":"The Lancet."},{"issue":"1","key":"2023090111593252300_CIT0027","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J Hepatol."},{"key":"2023090111593252300_CIT0028","doi-asserted-by":"crossref","first-page":"e0252286","DOI":"10.1371\/journal.pone.0252286","article-title":"Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: a Taiwanese retrospective cohort study","volume":"16","author":"Yen","year":"2021","journal-title":"PLoS One."},{"issue":"9","key":"2023090111593252300_CIT0029","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/ajg.2013.163","article-title":"Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis","volume":"108","author":"Singh","year":"2013","journal-title":"Am J Gastroenterol."},{"issue":"5","key":"2023090111593252300_CIT0030","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.crohns.2011.04.011","article-title":"Fulminant ulcerative colitis despite maximal immunosuppression following liver transplantation: a case report and literature review","volume":"5","author":"Pan","year":"2011","journal-title":"J. Crohns Colitis."},{"issue":"11","key":"2023090111593252300_CIT0031","first-page":"741","article-title":"Infectious complications after liver transplantation","volume":"11","author":"Hernandez","year":"2015","journal-title":"Gastroenterol Hepatol."},{"issue":"6","key":"2023090111593252300_CIT0032","first-page":"949","article-title":"Safety of combination biologic and antirejection therapy post\u2013liver transplantation in patients with inflammatory bowel disease","volume":"26","author":"Al Draiweesh","year":"2019","journal-title":"Inflamm Bowel Dis."},{"issue":"10","key":"2023090111593252300_CIT0033","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1136\/gut.2006.114363","article-title":"Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine","volume":"56","author":"Vernier-Massouille","year":"2007","journal-title":"Gut."},{"issue":"11","key":"2023090111593252300_CIT0034","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1002\/(SICI)1521-4141(199811)28:11<3499::AID-IMMU3499>3.0.CO;2-Q","article-title":"TNF-induced enterocyte apoptosis in mice is mediated by the TNF receptor 1 and does not require p53","volume":"28","author":"Piguet","year":"1998","journal-title":"Eur J Immunol."},{"key":"2023090111593252300_CIT0035","author":"National Institute of Diabetes and Digestive and Kidney Disease","year":"2012"},{"issue":"3","key":"2023090111593252300_CIT0036","first-page":"602","article-title":"Risk of drug-induced liver injury from tumor necrosis factor antagonists","volume":"13","author":"Bj\u00f6rnsson","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"issue":"5","key":"2023090111593252300_CIT0037","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41397-020-0159-0","article-title":"HLA associations with infliximab-induced liver injury","volume":"20","author":"Bruno","year":"2020","journal-title":"Pharmacogenomics J."},{"issue":"1","key":"2023090111593252300_CIT0038","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4065\/76.1.84","article-title":"Infliximab-associated reversible cholestatic liver disease","volume":"76","author":"Menghini","year":"2001","journal-title":"Mayo Clin Proc."},{"issue":"24","key":"2023090111593252300_CIT0039","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.3748\/wjg.v21.i24.7584","article-title":"Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: a single center report of 8 cases","volume":"21","author":"Rodrigues","year":"2015","journal-title":"World J Gastroenterol."},{"issue":"3","key":"2023090111593252300_CIT0040","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.crohns.2010.12.007","article-title":"Autoimmune hepatitis during infliximab therapy for Crohn\u2019s disease: a case report","volume":"5","author":"Doyle","year":"2011","journal-title":"J. Crohns Colitis."},{"issue":"37","key":"2023090111593252300_CIT0041","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.3748\/wjg.v25.i37.5676","article-title":"Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history","volume":"25","author":"Magr\u00ec","year":"2019","journal-title":"World J Gastroenterol."},{"issue":"3","key":"2023090111593252300_CIT0042","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/gut.2005.071118","article-title":"Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice","volume":"55","author":"Tomita","year":"2006","journal-title":"Gut."},{"issue":"2","key":"2023090111593252300_CIT0043","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10753-007-9053-z","article-title":"The treatment with antibody of TNF-\u03b1 reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet","volume":"31","author":"Koca","year":"2008","journal-title":"Inflammation."},{"issue":"8","key":"2023090111593252300_CIT0044","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/MEG.0000000000001144","article-title":"Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease: a meta-analysis","volume":"30","author":"Lapumnuaypol","year":"2018","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"8","key":"2023090111593252300_CIT0045","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1097\/MIB.0000000000000832","article-title":"Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease","volume":"22","author":"Bessissow","year":"2016","journal-title":"Inflamm Bowel Dis."},{"issue":"5","key":"2023090111593252300_CIT0046","first-page":"463","article-title":"High prevalence of non-alcoholic fatty liver disease in patients with inflammatory bowel disease receiving anti-tumor necrosis factor therapy","volume":"32","author":"Likhitsup","year":"2019","journal-title":"Ann. Gastroenterol."},{"issue":"8","key":"2023090111593252300_CIT0047","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/j.crohns.2012.10.015","article-title":"Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease","volume":"7","author":"Sourianarayanane","year":"2013","journal-title":"J. Crohns Colitis."},{"issue":"6","key":"2023090111593252300_CIT0048","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1136\/ard.2009.116194","article-title":"Hepatoprotective effect of tumour necrosis factor \u03b1 blockade in psoriatic arthritis: A cross-sectional study","volume":"69","author":"Seitz","year":"2010","journal-title":"Ann Rheum Dis."},{"issue":"12","key":"2023090111593252300_CIT0049","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1055\/s-2008-1027411","article-title":"Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH)","volume":"46","author":"Schramm","year":"2008","journal-title":"Z Gastroenterol."},{"issue":"1","key":"2023090111593252300_CIT0050","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"2023090111593252300_CIT0051","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Electronic address: easloffice@easloffice.eu & European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol."},{"issue":"44","key":"2023090111593252300_CIT0052","doi-asserted-by":"crossref","first-page":"7867","DOI":"10.3748\/wjg.v19.i44.7867","article-title":"Tumor necrosis factor-\u03b1 inhibitors and chronic hepatitis C: a comprehensive literature review","volume":"19","author":"Pompili","year":"2013","journal-title":"World J Gastroenterol."},{"issue":"9","key":"2023090111593252300_CIT0053","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/rheumatology\/ker190","article-title":"Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review","volume":"50","author":"Brunasso","year":"2011","journal-title":"Rheumatology"},{"issue":"1","key":"2023090111593252300_CIT0054","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/MCG.0b013e3181a745e7","article-title":"Adalimumab-induced autoimmune hepatitis","volume":"44","author":"Adar","year":"2010","journal-title":"J Clin Gastroenterol."},{"issue":"10","key":"2023090111593252300_CIT0055","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1136\/ard.2004.032821","article-title":"Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis","volume":"64","author":"Germano","year":"2005","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"2023090111593252300_CIT0056","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2012.11.010","article-title":"Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis","volume":"58","author":"Weiler-Normann","year":"2013","journal-title":"J Hepatol."},{"issue":"1","key":"2023090111593252300_CIT0057","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/MPG.0000000000001759","article-title":"& Mieli-Vergani, G. Anti-TNF\u03b1 treatment in children and adolescents with combined inflammatory bowel disease and autoimmune liver disease","volume":"66","author":"Nedelkopoulou","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"9","key":"2023090111593252300_CIT0058","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.gastrohep.2014.02.012","article-title":"Onset of severe acute autoimmune hepatitis refractory to conventional treatment, rescued with infliximab","volume":"37","author":"Vallejo Senra","year":"2014","journal-title":"Gastroenterol Hepatol."},{"issue":"4","key":"2023090111593252300_CIT0059","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2013.05.046","article-title":"Infliximab as rescue therapy in paediatric autoimmune hepatitis","volume":"59","author":"Rajanayagam","year":"2013","journal-title":"J Hepatol."},{"issue":"9","key":"2023090111593252300_CIT0060","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2169\/internalmedicine.51.6824","article-title":"Adult-onset Still\u2019s disease complicated by autoimmune hepatitis: successful treatment with infliximab","volume":"51","author":"Fujii","year":"2012","journal-title":"Intern. Med. Tokyo Jpn"},{"issue":"4","key":"2023090111593252300_CIT0061","first-page":"590","article-title":"Improvement of liver function tests in patients with primary sclerosing cholangitis and Crohn\u2019s disease treated with infliximab","volume":"19","author":"Regueiro","year":"2003","journal-title":"Gastroenterology."},{"issue":"5","key":"2023090111593252300_CIT0062","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/MCG.0b013e3181662426","article-title":"A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis","volume":"42","author":"Hommes","year":"2008","journal-title":"J Clin Gastroenterol."},{"issue":"2","key":"2023090111593252300_CIT0063","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/apt.14829","article-title":"Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease","volume":"48","author":"Tse","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"issue":"10","key":"2023090111593252300_CIT0064","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.cgh.2020.02.014","article-title":"Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis","volume":"18","author":"Hedin","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"5","key":"2023090111593252300_CIT0065","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/MEG.0000000000000596","article-title":"Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options","volume":"28","author":"Franceschet","year":"2016","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"10","key":"2023090111593252300_CIT0066","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/ibd\/izaa317","article-title":"Association of anti-TNF therapy with increased risk of acute cholangitis in patients with primary sclerosing cholangitis","volume":"27","author":"Kulkarni","year":"2021","journal-title":"Inflamm Bowel Dis."},{"issue":"6","key":"2023090111593252300_CIT0067","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jhep.2008.07.027","article-title":"Genetic factors of susceptibility and of severity in primary biliary cirrhosis","volume":"49","author":"Poupon","year":"2008","journal-title":"J Hepatol."},{"issue":"2","key":"2023090111593252300_CIT0068","first-page":"101","article-title":"Crohn\u2019s disease of the small bowel, complicated by primary biliary cirrhosis, Hashimoto thyroiditis, and Raynaud\u2019s phenomenon: Favorable response of all disorders to adalimumab treatment","volume":"6","author":"Triantafillidis","year":"2013","journal-title":"Gastroenterol. Hepatol. Bed Bench."},{"issue":"11","key":"2023090111593252300_CIT0069","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s00296-015-3366-2","article-title":"Infliximab as a treatment option for patients with rheumatoid arthritis and primary biliary cirrhosis","volume":"35","author":"Dimopoulou","year":"2015","journal-title":"Rheumatol Int"},{"key":"2023090111593252300_CIT0070","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jbspin.2007.03.003","article-title":"Effect of tumor necrosis factor alpha antagonists in a patient with rheumatoid arthritis and primary biliary cirrhosis","volume":"75","author":"Spadaro","year":"2008","journal-title":"Joint Bone Spine."},{"issue":"5","key":"2023090111593252300_CIT0071","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/17843286.2017.1290567","article-title":"Successful infliximab therapy in a patient with comorbid spondyloarthritis, primary biliary cirrhosis and generalized morphea","volume":"72","author":"Resorlu","year":"2017","journal-title":"Acta Clin Belg."},{"issue":"5","key":"2023090111593252300_CIT0072","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/ecco-jcc\/jjv045","article-title":"Administration of two anti-TNF-\u03b1 agents in an ulcerative colitis patient with HBV-related cirrhosis","volume":"9","author":"Desideri","year":"2015","journal-title":"J. Crohns Colitis."},{"issue":"3","key":"2023090111593252300_CIT0073","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.crohns.2008.05.008","article-title":"Infliximab use in a patient with ulcerative colitis and alcoholic cirrhosis with portal hypertension","volume":"2","author":"Carri\u00f3n","year":"2008","journal-title":"J. Crohn\u2019s and Colitis"},{"issue":"2","key":"2023090111593252300_CIT0074","first-page":"512","article-title":"Safety and efficacy of biological therapies in patients with psoriasis with alcoholic cirrhosis: a French retrospective study of 23 cases","volume":"179","author":"Begon","year":"2018","journal-title":"Br. J. Dermatol"},{"issue":"2","key":"2023090111593252300_CIT0075","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.transproceed.2017.09.069","article-title":"Efficacy and safety of anti-TNF-\u03b1 agents in inflammatory bowel disease after liver transplant: a case series","volume":"50","author":"Olmedo-Mart\u00edn","year":"2018","journal-title":"Transplant Proc."},{"issue":"7","key":"2023090111593252300_CIT0076","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.dld.2018.02.014","article-title":"Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: a nationwide case series","volume":"50","author":"Altwegg","year":"2018","journal-title":"Dig Liver Dis."},{"issue":"2","key":"2023090111593252300_CIT0077","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2036.2012.05141.x","article-title":"The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series","volume":"36","author":"Sandhu","year":"2012","journal-title":"Aliment Pharmacol Ther."},{"issue":"9","key":"2023090111593252300_CIT0078","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/ecco-jcc\/jjx057","article-title":"Safety of anti-TNF treatment in liver transplant recipients: a systematic review and meta-analysis","volume":"11","author":"Westerouen van Meeteren","year":"2017","journal-title":"J. Crohns Colitis."},{"issue":"6","key":"2023090111593252300_CIT0079","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2036.2012.05217.x","article-title":"Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients","volume":"36","author":"Mohabbat","year":"2012","journal-title":"Aliment Pharmacol Ther."},{"issue":"8","key":"2023090111593252300_CIT0080","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med."},{"issue":"2","key":"2023090111593252300_CIT0081","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/ecco-jcc\/jjz137","article-title":"The safety profile of vedolizumab in ulcerative colitis and crohn\u2019s disease: 4 years of global post-marketing data","volume":"14","author":"Cohen","year":"2020","journal-title":"J. Crohns Colitis"},{"issue":"4","key":"2023090111593252300_CIT0082","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/ecco-jcc\/jjz159","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in a patient with hcv-induced porphyria cutanea tarda receiving vedolizumab for crohn\u00b4s disease","volume":"14","author":"Rojo","year":"2020","journal-title":"J. Crohns Colitis."},{"issue":"1","key":"2023090111593252300_CIT0083","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cgh.2019.05.013","article-title":"Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases","volume":"18","author":"Lynch","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"3","key":"2023090111593252300_CIT0084","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J Hepatol."},{"issue":"6","key":"2023090111593252300_CIT0085","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/apt.14525","article-title":"Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease","volume":"47","author":"Christensen","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"issue":"10","key":"2023090111593252300_CIT0086","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/ecco-jcc\/jjz088","article-title":"Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: a GETAID multicentre cohort study","volume":"13","author":"Caron","year":"2019","journal-title":"J. Crohns Colitis."},{"issue":"7","key":"2023090111593252300_CIT0087","first-page":"e3080","article-title":"The use of vedolizumab in patients with concomitant cirrhosis and Crohn\u2019s Disease","volume":"10","author":"Kapila","year":"2018","journal-title":"Cureus."},{"issue":"7","key":"2023090111593252300_CIT0088","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/2050640619858050","article-title":"Safety of vedolizumab in liver transplant recipients: a systematic review","volume":"7","author":"Spadaccini","year":"2019","journal-title":"United Eur. Gastroenterol. J."},{"issue":"16","key":"2023090111593252300_CIT0089","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med."},{"issue":"6","key":"2023090111593252300_CIT0090","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/bjd.12461","article-title":"The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C","volume":"169","author":"Chiu","year":"2013","journal-title":"Br J Dermatol."},{"issue":"9","key":"2023090111593252300_CIT0091","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s40261-018-0671-z","article-title":"Risk of Hepatitis B reactivation in patients with psoriasis on ustekinumab","volume":"38","author":"Ting","year":"2018","journal-title":"Clin Drug Investig."},{"issue":"3","key":"2023090111593252300_CIT0092","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/bjd.12045","article-title":"Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting","volume":"168","author":"Navarro","year":"2013","journal-title":"Br J Dermatol."},{"issue":"24","key":"2023090111593252300_CIT0093","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1056\/NEJMoa0810440","article-title":"Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants","volume":"360","author":"Hirschfield","year":"2009","journal-title":"N Engl J Med."},{"issue":"1","key":"2023090111593252300_CIT0094","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep.28359","article-title":"Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study","volume":"64","author":"Hirschfield","year":"2016","journal-title":"Hepatology."},{"issue":"11","key":"2023090111593252300_CIT0095","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1111\/ijd.14556","article-title":"Safety of systemic therapies in the treatment of psoriasis with concomitant cirrhosis: a retrospective study","volume":"58","author":"Blaszczak","year":"2019","journal-title":"Int J Dermatol."},{"issue":"10","key":"2023090111593252300_CIT0096","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/ecco-jcc\/jjaa062","article-title":"Ustekinumab is a safe and effective biologic agent for Crohn\u2019s disease in a Liver Transplant patient","volume":"14","author":"Peverelle","year":"2020","journal-title":"J. Crohns Colitis."},{"issue":"9","key":"2023090111593252300_CIT0097","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/ecco-jcc\/jjv109","article-title":"Ustekinumab is effective and safe in the treatment of Crohn\u2019s disease refractory to anti-TNF-\u03b1 in an orthotopic liver transplant patient","volume":"9","author":"Mart\u00ednez-Montiel","year":"2015","journal-title":"J. Crohns Colitis."},{"issue":"12","key":"2023090111593252300_CIT0098","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1093\/ibd\/izab169","article-title":"Safety and efficacy of ustekinumab for ulcerative colitis in a liver transplant patient","volume":"27","author":"Shibuya","year":"2021","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"2023090111593252300_CIT0099","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/apt.15072","article-title":"Long-term safety and tolerability of oral tofacitinib in patients with Crohn\u2019s disease: results from a phase 2, open-label, 48-week extension study","volume":"49","author":"Pan\u00e9s","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"issue":"5","key":"2023090111593252300_CIT0100","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/annrheumdis-2017-211322","article-title":"Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study","volume":"77","author":"Chen","year":"2018","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"2023090111593252300_CIT0101","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/1756-185X.14217","article-title":"Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib","volume":"24","author":"Wang","year":"2021","journal-title":"Int. J. Rheum. Dis"},{"issue":"6","key":"2023090111593252300_CIT0102","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/annrheumdis-2018-214400","article-title":"Comparisons of hepatitis C viral replication in patients with rheumatoid arthritis receiving tocilizumab, abatacept and tofacitinib therapy","volume":"78","author":"Chen","year":"2019","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"2023090111593252300_CIT0103","doi-asserted-by":"crossref","first-page":"7047","DOI":"10.4049\/jimmunol.0900547","article-title":"SOCS3 in T and NKT cells negatively regulates cytokine production and ameliorates ConA-induced hepatitis","volume":"183","author":"Nakaya","year":"2009","journal-title":"J Immunol."},{"issue":"4","key":"2023090111593252300_CIT0104","doi-asserted-by":"crossref","first-page":"86","DOI":"10.33878\/2073-7556-2019-18-4-86-99","article-title":"Experience of tofacitinib using in therapy of ulcerative colitis in real clinical practice","volume":"18","author":"Belousova","year":"2019","journal-title":"Koloproktologia."},{"key":"2023090111593252300_CIT0105","doi-asserted-by":"crossref","first-page":"S1159","DOI":"10.14309\/01.ajg.0000597832.37375.24","article-title":"2075 tandem therapy using cyclosporine and tofacitinib for the treatment of severe ulcerative colitis","volume":"114","author":"Cleveland","year":"2019","journal-title":"Am J Gastroenterol."},{"key":"2023090111593252300_CIT0106","doi-asserted-by":"crossref","DOI":"10.1055\/s-0041-1740704","article-title":"Safety and efficacy of the JAK-inhibitor tofacitinib in patients with primary sclerosing cholangitis: a multicentre, retrospective study","author":"Schregel","year":"2022"},{"issue":"6","key":"2023090111593252300_CIT0107","doi-asserted-by":"crossref","first-page":"S-450-S-451","DOI":"10.1016\/S0016-5085(20)31809-6","article-title":"Sa1850 colitis patients with PSC may gain additional benefit from the use of tofacitinib","volume":"158","author":"Lewis","year":"2020","journal-title":"Gastroenterology."},{"issue":"4","key":"2023090111593252300_CIT0108","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/ecco-jcc\/jjaa032","article-title":"Use of tofacitinib for ulcerative colitis in a liver transplant patient","volume":"15","author":"Meunier","year":"2021","journal-title":"J. Crohns Colitis."},{"issue":"14","key":"2023090111593252300_CIT0109","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med."},{"key":"2023090111593252300_CIT0110","doi-asserted-by":"crossref","first-page":"102844","DOI":"10.1016\/j.msard.2021.102844","article-title":"Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program","volume":"51","author":"Selmaj","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"2023090111593252300_CIT0111","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatol. Baltim. Md."},{"key":"2023090111593252300_CIT0112"},{"issue":"2019","key":"2023090111593252300_CIT0113","article-title":"Frequency of hepatobiliary manifestations and concomitant liver disease in inflammatory bowel disease patients","volume":"7604939","author":"Silva","year":"2019","journal-title":"Biomed Res Int."},{"issue":"10","key":"2023090111593252300_CIT0114","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/jgh.14746","article-title":"Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population","volume":"34","author":"Lv","year":"2019","journal-title":"J Gastroenterol Hepatol."},{"key":"2023090111593252300_CIT0115","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1093\/ibd\/izac015.072","article-title":"Incidence and prevalence of primary sclerosing cholangitis: a meta-analysis of population-based studies","volume":"28","author":"Cooper","year":"2022","journal-title":"Inflamm Bowel Dis."},{"issue":"5","key":"2023090111593252300_CIT0116","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","article-title":"Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review","volume":"56","author":"Boonstra","year":"2012","journal-title":"J Hepatol."},{"issue":"13","key":"2023090111593252300_CIT0117","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.3748\/wjg.v12.i13.2115","article-title":"Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies","volume":"12","author":"Ogren","year":"2006","journal-title":"World J Gastroenterol."},{"issue":"12","key":"2023090111593252300_CIT0118","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.cgh.2019.07.060","article-title":"Contemporary epidemiology of chronic liver disease and cirrhosis","volume":"18","author":"Moon","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2023090111593252300_CIT0119"},{"issue":"12","key":"2023090111593252300_CIT0120","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.4254\/wjh.v13.i12.1828","article-title":"Liver-side of inflammatory bowel diseases: hepatobiliary and drug-induced disorders","volume":"13","author":"Mazza","year":"2021","journal-title":"World J. Hepatol."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izac189\/45625710\/izac189.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/29\/9\/1477\/51317392\/izac189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/29\/9\/1477\/51317392\/izac189.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T12:53:37Z","timestamp":1693572817000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/29\/9\/1477\/6679142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":120,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,8,30]]},"published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izac189","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2022,8,30]]}}}